Nebenwirkungen · Toviaz
TOVIAZ 4 mg prolonged-release tablets TOVIAZ 8 mg prolonged-release tablets · Abschnitt 4.8 · PDF-Seite 6
HOS-117272 · Präparat HOS-094561
Dry mouth, the only very common adverse reactions, occurred with a frequency of 28.8% in the fesoterodine group compared to 8.5% in the placebo group. The majority of adverse reactions occurred during the first month of treatment with the exception of cases classified as urinary retention or post void residual urine greater than 200 ml, which could occur after long term treatment and was more common in male than female subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-04T15:52:00Z · SHA-256 c9fd9fb2f6c8ee3d5e56c913ba09d40147211dee6df16329539fa6b5e813accb · Passage b64d4662dba06e972c7cacd540a2e78116d1d4ad5ef244161190336791e8bc37 · Zeichen 404–836 im Abschnitt